Passage Bio, Inc. — Form 8-K Summary
Business context and reporting period
This Form 8-K, filed June 1, 2022, reports events occurring on or around the May 26, 2022 annual meeting and the May 31, 2022 transition of the company’s president and chief executive officer. The filing does not provide quarterly or annual financial statements.
Key financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material compensation and equity terms disclosed include:
- Bruce Goldsmith will receive a $50,000 monthly advisory fee through September 1, 2022, subject to the transition arrangements.
- Subject to a general release and other conditions, Mr. Goldsmith will receive a $566,500 lump-sum payment, healthcare continuation support for 12 months, a pro rata 2022 bonus, specified option vesting and exercise-period extensions, and a new option to purchase 100,000 shares at $1.86 per share.
- Interim CEO and President Edgar B. (Chip) Cale received a $15,000 monthly base-salary increase and a 100,000-share option grant vesting monthly over 12 months at an exercise price of $1.80 per share.
- Interim Executive Chairwoman Maxine Gowen will receive $20,000 per month and a 40,000-share option grant vesting monthly over 12 months at an exercise price of $1.80 per share.
Material changes versus the prior comparable period
- Bruce Goldsmith ceased serving as President and CEO and resigned from the Board effective May 31, 2022, pursuant to a mutual agreement. The filing states that the transition was not related to misconduct, policy violations, accounting irregularities, or disagreements regarding strategy, operations, policies, or practices.
- The Board began a search for a permanent CEO and appointed Mr. Cale as Interim CEO and President.
- Ms. Gowen became Interim Executive Chairwoman and ceased serving on the Compensation Committee and Nominating and Corporate Governance Committee while holding that role.
- At the May 26, 2022 annual meeting, stockholders elected Maxine Gowen and Thomas Woiwode as Class II directors for terms expiring at the 2025 annual meeting.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, outlook, risks, contingencies, and unusual items
No financial guidance or operating outlook was provided. The principal near-term uncertainty is the timing and outcome of the search for a permanent CEO.
The transition arrangements create additional cash compensation, healthcare, bonus, and equity-award obligations. Mr. Cale’s employment agreement also provides severance and certain equity-acceleration benefits upon qualifying termination or specified changes in control. The transition agreement will be filed with the company’s Form 10-Q for the six months ending June 30, 2022.
The filing date is May 26, 2022, but it describes a May 27 transition agreement and actions effective May 31, 2022; investors should verify the relevant event dates in the filed exhibits and subsequent reports.
Important facts for investors to verify
- Progress of the permanent CEO search and the duration of Mr. Cale’s interim appointment.
- The final terms and accounting impact of Mr. Goldsmith’s separation and equity-award modifications.
- The expected cash cost and stock-compensation expense associated with the transition arrangements and new option grants.
- Any subsequent disclosures regarding liquidity, financing needs, clinical development, or business outlook, none of which are provided in this filing.
- The transition agreement and related exhibits when filed with the subsequent Form 10-Q.